Bishu Ganguly
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Radiopharmaceutical Chemistry and Applications, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research
Most-Cited Works
- → Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma(2019)178 cited
- → Proteolysis results in altered leak channel kinetics and elevated free calcium in mdx muscle(1993)100 cited
- → Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease(2017)70 cited
- → Immunomodulatory activity of humanized anti–IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes(2019)40 cited
- → First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.(2016)33 cited
- → Glycosylated recombinant human XCL1/lymphotactin exhibits enhanced biologic activity(2005)27 cited
- → The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).(2017)20 cited
- → Transcriptional Profiling of Belatacept and Calcineurin Inhibitor Therapy in Renal Allograft Recipients(2014)17 cited
- → Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator(2016)16 cited
- → A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies(2016)15 cited